In the last trading session, 6.71 million Mersana Therapeutics Inc (NASDAQ:MRSN) shares changed hands as the company’s beta touched 1.63. With the company’s per share price at $0.53 changed hands at $0.0 or 0.98% during last session, the market valuation stood at $65.87M. MRSN’s last price was a discount, traded about -1084.91% off its 52-week high of $6.28. The share price had its 52-week low at $0.49, which suggests the last value was 7.55% up since then.
Analysts gave the Mersana Therapeutics Inc (MRSN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.36. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended MRSN as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. Mersana Therapeutics Inc’s EPS for the current quarter is expected to be -0.17.
Mersana Therapeutics Inc (NASDAQ:MRSN) trade information
Instantly MRSN was in green as seen at the end of in last trading. With action -12.49%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -62.71%, with the 5-day performance at -12.49% in the red. However, in the 30-day time frame, Mersana Therapeutics Inc (NASDAQ:MRSN) is 1.08% up.
The consensus price target for the stock as assigned by Wall Street analysts is 3, meaning bulls need an upside of 82.33% from its current market value. According to analyst projections, MRSN’s forecast low is 3 with 3 as the target high. To hit the forecast high, the stock’s price needs a -466.04% plunge from its current level, while the stock would need to soar -466.04% for it to hit the projected low.
Mersana Therapeutics Inc (MRSN) estimates and forecasts
Year-over-year growth is forecast to reach -15.79% down from the last financial year.
Consensus estimates given by 9 financial analysts project the company’s revenue in the current quarter to hit an average of 7.71M. 6 analysts are of the opinion that Mersana Therapeutics Inc’s revenue for the current quarter will be 5.2M. The company’s revenue for the corresponding quarters a year ago was 10.7M and 9.24M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -27.93%. The estimates for the next quarter sales put growth at -43.78%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 11.93%. The 2025 estimates are for Mersana Therapeutics Inc earnings to increase by 58.87%, but the outlook for the next 5-year period is at 20.92% per year.
Mersana Therapeutics Inc (NASDAQ:MRSN)’s Major holders
VR ADVISER, LLC holds the second largest percentage of outstanding shares, with 9.2519% or 11.33 million shares worth $22.77 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. With 3.47 shares estimated at $1.85 million under it, the former controlled 2.81% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 2.60% of the shares, roughly 3.22 shares worth around $1.72 million.
